Functional and Pharmacokinetic Outcomes after a Single Intravenous Infusion of Recombinant Human Erythropoietin in Patients with Malignant Extradural Spinal Cord Compression

Clinical Oncology

Volumn 19, Issue 1, 2007, Pages 63-70

  Loblaw, D A ^a   Holden, L ^a   Xenocostas, A ^b   Chen, E ^c   Chander, S ^a   Cooper, P ^a   Chan, P C ^d   Wong, C S ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Erythropoietin; malignant spinal cord compression; outcomes research; palliation; radiotherapy

Indexed keywords

DEXAMETHASONE; RECOMBINANT ERYTHROPOIETIN; STEROID;

ADULT; AGED; ARTICLE; BRAIN FUNCTION; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG FATALITY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; LUMBAR PUNCTURE; LUNG EMBOLISM; MALE; MALIGNANT EXTRADURAL SPINAL CORD COMPRESSION; MALIGNANT NEOPLASTIC DISEASE; MOBILIZATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSORY DYSFUNCTION; SINGLE DRUG DOSE; SPINAL CORD COMPRESSION; TREATMENT OUTCOME; VEIN PUNCTURE;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; DEXAMETHASONE; EPOETIN ALFA; FEMALE; GLUCOCORTICOIDS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PAIN; PALLIATIVE CARE; PARAPARESIS; SPINAL CORD COMPRESSION; SPINAL NEOPLASMS; SURVIVAL RATE;

EID: 33846004434     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2006.10.009     Document Type: Article

References (37)

1. Loblaw D.A., Laperriere N.J., and Mackillop W.J. A population-based study of malignant spinal cord compression in Ontario. Clin Oncol 15 4 (2003) 211-217
2. Loblaw D.A., and Laperiere N.J. Emergency treatment of malignant extradural spinal cord compression: an evidence-based guideline. J Clin Oncol 16 4 (1998) 1613-1624
3. Kim R.Y., and Spencer S.A. Extradural spinal cord compression: analysis of factors determining functional prognosis - prospective study. Radiol 176 (1990) 279-282
4. Helwig-Larsen S., Sorensen P.S., and Kreiner S. Prognostic factors in metastatic spinal cord compression: a prospective study using multivariate analysis of variables influenceing survival and gait function in 153 patients. Int J Rad Oncol Biol Phys 46 5 (2000) 1163-1169
5. Bernaudin M., Bellail A., Marti H.H., et al. Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain. Glia 30 3 (2000) 271-278
6. Brines M.L., Ghezzi P., Keenan S., et al. Erythropoetin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97 (2000) 10526-10531
7. Lipton S.A. Erythropoietin for neurologic protection and diabetic neuropathy. N Engl J Med 350 24 (2004) 2516-2517
8. Littlewood T.J., Bajetta E., Nortier J.W.R., Varcammen E., and Rapoport B. for the Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized double-blind, placebo-controlled trial. J Clin Oncol 19 11 (2001) 2865-2874
9. Quirt I., Robeson C., Lau C.Y., et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 19 21 (2001) 4126-4134
10. Celik M., Gokmen N., Erbayraktar S., et al. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. PNAS 99 4 (2002) 2258-2263
11. Ehrenreich H., Hasselblatt M., Piotr L., et al. Erythropoetin treatment for acute stroke: a randomized double-blind proof-of-concept trial in man. Stroke 33 1 (2001) 324
12. Colton T. Statistics in Medicine (1974), Little, Brown and Company, Boston
13. Rades D., Heidenreich F., and Karstens J.H. Final results of a prospective study of the prognostic value of the time to develop motor deficits before irradiation in metastatic spinal cord compression. Int J Radiat Oncol Biol Phys 53 (2002) 975-979
14. Reiber H. The discrimination between different blood-CSF barrier dysfunctions and inflammatory reactions of the CNS by a recent evaluation graph for the protein profile of cerebrospinal fluid. J Neurol 224 (1980) 89-99
15. Chow E., Wu J.S., Hoskin P., Coia L.R., Bentzen S.M., and Blitzer P.H. International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother Oncol 64 3 (2002) 275-280
16. Mitera G., and Loblaw D.A. Delays from symptom onset to treatment in malignant spinal cord compression: quantification and effect on pre-treatment neurological status. Proc Amer Soc Clin Oncol 23 (2004) 119 (abstract 8276)
17. Xenocostas A., Cheung W.K., Farrell F., et al. The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin. Eur J Clin Pharmacol 61 3 (2005) 189-195
18. Rades D., Karstens J.H., and Alberti W. Role of radiotherapy in the treatment of motor dysfunction due to metastatic spinal cord compression: comprarison of three different fractionation schedules. Int J Rad Onc Biol Phys 54 4 (2002) 1160-1164
19. Loblaw D.A., and Laperriere N.J. The Princess Margaret Hospital Experience of malignant spinal cord compression. Proc Amer Soc Clin Oncol 22 (2003) 119 (abstract 477)
20. Woolf S.H., Battista R.N., Anderson G.M., et al. Assessing the clinical effectiveness of preventative maneuvers: analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations. J Clin Epi 43 9 (1990) 891-905
21. Woolf S.H., and Haggerty J. A systematic methodology for reviewing the evidence. Checklists for task force reviews (1988), Canadian Task Force on the Periodic Health Examiniation, Toronto
22. Loblaw D.A., Perry J., Chambers A., and Laperriere N.J. Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group. J Clin Oncol 23 9 (2005) 2028-2037
23. Benson K., and Hartz A.J. A comparison of observational studies and randomized, controlled trials. N Engl J Med 342 25 (2000) 1878-1886
24. Concato J., Shah N., and Horwitz R.I. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 342 25 (2000) 1887-1892
25. Maranzano E., Latini P., Checcaglini F., et al. Radiation therapy in metastatic spinal cord compression. A prospective analysis of 105 consecutive patients. Ann Neurol 3 (1991) 40-51
26. Maranzano E., and Latini P. Effectiveness of radiation therapy without surgery in metastatic spinal cord compression: final results from a prospective trial. International Journal of Radiation Oncology, Biology, Physics 32 4 (1995) 959-967
27. Helweg-Larsen. Clinical outcome in metastatic spinal cord compression. A prospective study of 153 patients. Acta Neurol Scand 94 (1996) 264-275
28. Maranzano E., Latini P., Beneventi S., et al. Radiotherapy without steroids in selected metastatic spinal cord compression patients. A phase II trial. American Journal of Clinical Oncology 19 2 (1996) 179-183
29. Maranzano E., Latini P., Beneventi S., et al. Comparison of two different kinds of radiotherapy schedules for spinal cord compression. Tumori 84 (1998) 472-477
30. Kovner F., Spigel S., Rider I., et al. Radiation therapy of metastatic spinal cord compression. J Neuroonc 42 (1999) 85-92
31. Patchell R., Tibbs P.A., Regine W.F., et al. A randomized trial of direct decompressive surgical resection in the treatment of spinal cord compression caused by metastases. Proc ASCO 22 (2003) 1 (abstract 2)
32. Shingo T., Sorokan S.T., Shimazaki T., and Weiss S. Erythropoietin Regulates the In Vitro and In Vivo Production of Neuronal Progenitors by Mammalian Forebrain Neural Stem Cells. The Journal of Neuroscience 21 4 (2001) 9733-9743
33. Bahlmann F.H., De Groot K., Spandau J.M., et al. Erythropoietin regulates endothelial progenitor cells. Blood 103 3 (2004) 921-926
34. Anagnostou A., Lee E.S., Kessimian N., and R Levinson M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A 87 15 (1990) 5978-5982
35. Heeschen C., Aicher A., Lehmann R., et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102 4 (2003) 1340-1346
36. Farrell F., and Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 9 Suppl 5 (2004) 18-30
37. Bohlius J., Langensiepen S., Schwarzer G., et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 97 7 (2005) 489-498